Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Go online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies in the adjuvant and neoadjuvant settings are under way as well. How should these advances be transitioned to the clinic based on the accumulating supportive evidence? How can surgeons and oncologists work together to ensure proper risk assessment and treatment planning to improve outcomes in patients with HR+/HER2- EBC? This PeerView Virtual Workshop provides pertinent updates on the most recent research and available evidence on CDK4 and 6 inhibition in HR+/HER2- EBC, as well as practical, case-based guidance on the application of these agents using individualized treatment plans and effective multidisciplinary collaboration. Upon completion of this CE activity, participants will be able to: Discuss the presentation, evaluation, diagnosis, staging, and stratification of early breast cancer (EBC) as well as emerging prognostic and predictive markers and factors that influence the risk of recurrence, Integrate the latest safety, efficacy, predictive/prognostic, and other clinically important data from studies investigating CDK4 & 6 inhibitor therapy and combinations in patients with HR+/HER2- EBC, including those with high-risk disease, Incorporate up-to-date guidance, multigene assays, risk assessment algorithms, and evidence-based treatment options into personalized management plans that leverage shared decision-making and multidisciplinary and interprofessional team based approaches to optimize care for patients with HR+/HER2- EBC, including patients with high-risk disease.